• By Aaron Gin —

    USPTO SealOn February 14, 2023, the U.S. Patent and Trademark Office published a notice in the Federal Register (88 Fed. Reg. 9492) requesting public comments about 1) the current state of Artificial Intelligence (AI) and Emerging Technologies (ET); and 2) associated inventorship issues that may arise with the advance of such technologies.

    The notice outlines the motivation and context for the request for comments.  Namely, the notice describes the USPTO-organized AI/ET Partnership meeting held in June 2022.  During that meeting, a panel session on "Inventorship and the Advent of Machine Generated Inventions" led to conversations about AI's increasing role in innovation in areas such as drug discovery, chip design, etc.  Meeting contributors identified situations in which AI systems can output patentable inventions or contribute at the level of a joint inventor.  Additionally, the notice provides a brief summary of recent District Court and Federal Circuit cases regarding the inventorship of AI generated inventions.  Yet further, the notice references calls from Senators Coons and Tillis to create a USPTO / U.S. Copyright Office national commission to consider changes in existing law to incentivize AI-related innovations and creations.

    The notice offers further stakeholder engagement sessions around AI-enabled innovations and inventorship.  Additionally, the notice encourages academic scholarship around these topics and announces plans to publish a special issue of the Journal of the Patent and Trademark Office Society.

    The notice includes several questions such as:

    1.  How is AI, including machine learning, currently being used in the invention creation process?
    2.  How does the use of an AI system in the invention creation process differ from the use of other technical tools?
    3.  If an AI system contributes to an invention at the same level as a human who would be considered a joint inventor, is the invention patentable under current patent laws?
    4.  Is there a need for the USPTO to expand its current guidance on inventorship to address situations in which AI significantly contributes to an invention?

    Comments must be submitted through the Federal eRulemaking Portal at www.regulations.gov, docket number PTO-P-2022-0045.

    For additional information regarding this topic, please see:

    • USPTO Alert, February 13, 2023
    • USPTO webpage on Artificial Intelligence

  • By Kevin E. Noonan –

    A change in the weather is known to be extreme
    But what's the sense of changing horses in midstream?
    I'm going out of my mind, oh, oh
    With a pain that stops and starts
    Like a corkscrew to my heart
    Ever since we've been apart

    "You're a Big Girl Now," Blood on the Tracks, Bob Dylan

    Federal Circuit SealIn perhaps one of his most infelicitous lyrics* Bob Dylan inserted the adage that it is unwise to change horses in midstream.  This lesson comes to mind with regard to the Federal Circuit's decision late last year regarding an attempt to pursue a new theory of infringement just weeks before trial would commence (which attempt failed) in Astellas US LLC v. Hospira, Inc.

    The case involved ANDA litigation brought by Gilead Sciences, Inc., Astellas US LLC and Astellas Pharma US, Inc. against Hospira for infringement of U.S. Patent Nos. 8,106,183; RE47,301; and 8,524,883 claiming a particular polymorph (termed Form A, a monohydrate) of regadenoson, an A2A adenosine receptor agonist that is a coronary vasodilator used to mimic cardiac stress and sold as Lexiscan®.  The formula for Hospira's generic regadenoson contained Form G as its active pharmaceutical ingredient (API) that would not infringe Astellas's asserted claim (the basis for Hospira's Paragraph IV certification), made by a process converting crude regadenoson to Form F (another polymorph) to Form G.  Plaintiff's initial theory of the case was that Hospira's generic drug nevertheless infringed the asserted claims, because Form A was made inadvertently by Hospira's third party supplier of an intermediate product and consequently the Form A polymorph was incorporated into Hospira's final generic product (on the basis that when these compounds "are exposed to a sufficient amount of water, including water in the air . . . and in reagents, they will convert to Form A").  In response to Hospira amending the Drug Master File (DMF) portion of its ANDA prior to trial (in an attempt to make Astellas's infringement showing harder to establish, wherein the new DMF recited that its manufacturing process had been optimized to "limit the presence of water"), Astellas asserted an alternative theory alleging that Form A arose as part of Hospira's compounding process in making its generic regadenoson.

    The District Court granted Hospira's motion to strike Astellas's newly presented infringement contentions and expert testimony and evidence, with the case going to trial on Astellas's original infringement theory.  The District Court found Hospira did not infringe according to Astellas's original infringement contentions, and Astellas appealed solely on the issue of whether the District Court's preventing their assertion of their alternative infringement theory and contentions and expert evidence associated therewith was an abuse of discretion.

    The Federal Circuit ruled that the District Court had not abused its discretion and affirmed the judgment in favor of Hospira, in an opinion by Judge Dyk joined by Judges Reyna and Cunningham.  The opinion notes that the District Court granted Astellas extra fact discovery in response to Hospira's change in its ANDA, but in addition to taking this discovery, Astellas submitted its new infringement contentions and expert evidence related to these contentions.  On the procedural issue of whether Astellas's motion was untimely, the Court recited the circumstances the panel relied upon in finding no abuse of discretion by the District Court.  These included testimony by Astellas's expert in the initial discovery phase that he was offering no opinion regarding whether Form A was made during Hospira's compounding process as well as several timing issues.  These included that Astellas proffered its alternative theory a year after the close of fact discovery and six months after expert discovery closed, and waited 14 months after Hospira's document disclosure, six months after learning of Hospira's ANDA change and two months after receiving Hospira's actual ANDA amendments.  In addition, Astellas waited "more than a month" after the District Court's grant of supplemental discovery prompted by Hospira's ANDA change.  Under these circumstances, the Federal Circuit stated that:

    There was no reason, other than Astellas's own litigation choices, that the compounding infringement theory could not have been asserted earlier.

    This is not a case where Astellas relied on new information disclosed in the ANDA amendment to craft a new theory of infringement.  Instead, Astellas simply decided that the ANDA amendment would make it harder to prove its original infringement theory and decided to try a new theory related to a process not changed by the amendment.

    Based in a supplementary discovery order the District Court had issued against another defendant (who later settled) in this case who had amended its ANDA, the Federal Circuit considered the supplementary discovery order here to have been limited to Hospira's changes to its ANDA and was not broad enough to be used to develop Astellas's alternative infringement theories or proffer expert evidence in support thereof, as well as representations by Astellas to the District Court regarding the limited extent of this discovery.  On this issue the Federal Circuit based its affirmance of the District Court striking Astellas's alternative infringement contention and expert evidence on  the "great deference . . . given to a district court's interpretation of its own order," citing WRS, Inc. v. Plaza Entertainment, Inc., 402 F.3d 424 (3rd Cir. 2005).

    The Federal Circuit similarly rejected Astellas's arguments that, timely or not, it was an abuse of the District Court's discretion to exclude its alternative theory of infringement.  Applying Third Circuit law, the Court considered whether Astellas had not satisfied the factors required in the Third Circuit under Meyers v. Pennypack Woods Home Ownership Assn, 559 F.2d 894 (3rd Cir. 1977):

    (1) "the prejudice or surprise in fact of the party against whom the excluded witnesses would have testified" or the excluded evidence would have been offered; (2) "the ability of that party to cure the prejudice"; (3) the extent to which allowing such witnesses or evidence would "disrupt the orderly and efficient trial of the case or of other cases in the court"; (4) any "bad faith or willfulness in failing to comply with the court's order"; and (5) the importance of the excluded evidence.

    Here, the Federal Circuit held that, while there was no finding under factor (4) of bad faith, the other factors supported the exercise of the District Court's discretion to preclude Astellas's alternative infringement theory.  These included clear evidence that Hospira was surprised by the alternative theory and was prejudiced thereby in view of the time remaining before trial, particularly in view of Astellas's expert's earlier testimony that he had no opinion regarding whether the Form A polymorph arose in Hospira's compounding process and there being insufficient time to perform the testing necessary to show that this conversion did not take place.  The Court also considered the prejudice to other parties to the litigation if the District Court postponed trial long enough for Hospira to complete this testing.  The opinion states that regarding factor (3) Astellas had not presented any persuasive evidence that the District Court erred in finding disruption of the court's calendar, and that Astellas had not shown that the evidence was sufficiently important to satisfy factor (5) (the opinion voicing reasons why the panel was not convinced that the excluded evidence would have been helpful for Astellas in establishing infringement).

    Ultimately the decision came down to the District Court's discretion, and the Federal Circuit was unwilling to second guess that court absent more compelling evidence than Astellas was able to provide.

    Astellas US LLC v. Hospira, Inc. (Fed. Cir. 2022)
    Nonprecedential disposition
    Panel: Circuit Judges Dyk, Reyna, and Cunningham
    Opinion by Circuit Judge Dyk

    * Of course he also wrote this lyric on that album, so maybe it was just a phase:

    They say I shot a man named Gray
    And took his wife to Italy
    She inherited a million bucks
    And when she died they came to me
    Can I help it if I'm lucky?

    "Idiot Wind"

  • By Donald Zuhn –-

    USPTO Eliminates CFR Provisions Regarding Voluntary CLE Certification

    USPTO SealIn a notice published in the Federal Register (88 Fed. Reg. 4906) last month, the U.S. Patent and Trademark Office issued a final rule adopting an interim final rule that the Office published in the Federal Register in November, that eliminated provisions of the Code of Federal Regulations related to voluntary continuing legal education (CLE) certification and recognition for registered patent practitioners and individuals granted limited recognition to practice in patent matters before the Office.  The final rule will take effect on February 27, 2023.

    The notice sets out a brief history of the voluntary CLE certification provision, recounting that in August 2020 the Office implemented 37 C.F.R. § 11.11(a)(3), which provided that patent practitioners could voluntarily certify completion of CLE to the USPTO Director for the Office of Enrollment and Discipline.  In October 2020, the Office published CLE guidelines, and then in June 2021, the Office published a notice that voluntary CLE certification would begin in the spring of 2022.  However, in December 2021, the Office published another notice that indefinitely delayed implementation of voluntary CLE certification, and in November 2022, the Office published the interim rule eliminating the voluntary CLE certification and recognition provisions from the CFR.  The most recent notice amends 37 C.F.R. § 11.11(a)(1) and (a)(3) to eliminate provisions concerning the voluntary CLE certification for registered patent practitioners and persons granted limited recognition to practice in patent matters before the Office under 37 C.F.R. § 11.9.

    The notice, however, also states that "[i]n the future, the Office may reconsider CLE reporting for patent practitioners, and nothing in this notice is intended to restrict or prohibit such action at a later time."


    USPTO, JPO, and KIPO Extend Expanded CSP Program

    JPOIn a notice published in the Federal Register (88 Fed. Reg. 2892) last month, the U.S. Patent and Trademark Office announced that the USPTO, Japan Patent Office (JPO), and Korean Intellectual Property Office (KIPO) have agreed to extend the Expanded Collaborative Search Pilot (CSP) program through October 31, 2024.  The Expanded CSP program provides Applicants who cross-file with the USPTO and either the JPO or KIPO with search results from each partner IP office early in the examination process.  The Program is designed to accelerate examination and provide Applicants with more comprehensive prior art by combining the search expertise of USPTO, JPO, and KIPO examiners before issuing a first Office action.  The USPTO noted that requests to participate in the Expanded CSP program that were filed between October 31, 2022 and January 18, 2023 will be considered.

    KIPO #2The USPTO also announced that in response to feedback provided by Applicants in the United States, Korea, and Japan that the petition process for the Expanded CSP program could be improved, specifically with respect to the requirement that Applicants petition each partner IP office separately, the USPTO, JPO, and KIPO developed combined petition forms:  PTO/437–JP for the USPTO/JPO pilot program and PTO/437–KR for the USPTO/KIPO pilot program.  Applicants wishing to participate in either the USPTO/JPO or USPTO/KIPO programs need only submit one petition to one of the two offices in each program.

    The changes to the Expanded CSP program took effect on January 18, 2023.  The notice also indicated that each partner IP office will continue to grant no more than 400 requests per year per partner office for the duration of the pilot.  In addition, the notice indicated that the request for participation in the Expanded CSP program must be granted by both the IP office in which the request is directly filed and the partner IP office prior to any examination of the counterpart applications in either office.  For additional information regarding the Expanded CSP, Applicants should consult the Expanded Collaborative Search Pilot Program Extension (86 Fed. Reg. 8183) that was published on February 4, 2021.


    USPTO Continues Email Address for PCT Questions

    USPTOIn a notice issued last month, the U.S. Patent and Trademark Office announced the extension of its pilot to provide an email address — PCTHelp@uspto.gov — for submitting inquiries about the Patent Cooperation Treaty (PCT) and international and national stage applications.  The email address will continue to be offered until January 1, 2024.

    According to the Office's notice, the email address is being offered to improve the overall customer service experience of those needing information regarding the PCT and international and national stage applications.  The Office notes that since 1993, it has also maintained a PCT Help Desk for telephonic inquiries regarding PCT issues.  The annual call volume at the PCT Help Desk has been as high as 40,910 calls per year, with an average of over 22,000 calls annually over the last three fiscal years.  The email address was created in response to customer feedback, which sought a reduction in wait times with the PCT Help Desk, an extension in the hours of availability of the PCT Help Desk to accommodate customers on the West Coast and overseas, and to better utilize modern communication mechanisms such as email.

    The Office notes that the email address is not intended for case-specific or time-sensitive inquiries, but rather is intended for general inquiries.

  • CalendarFebruary 14, 2023 – "Orange Book Listing Recent Developments — Impact on Prosecution of Pharmaceutical U.S. Patent Applications, Subsequent Orange Book Listings, Hatch Waxman Litigation" (Strafford) – 1:00 to 2:30 pm (EST)

    February 14, 2023 – "The Myth of the Meritocracy Part 2 — Countering Myths and Overcoming Bias" (Intellectual Property Owners Association) – 2:00 pm to 3:00 pm (ET)

    February 15, 2023 – "Best Practices for Searching Non-Patent Literature" (Patent Information Users Group, Inc.) – 10:00 am to 11:00 am (EST)

    February 15, 2023 – 2023 Patent Litigation Report (Lex Machina) – 9:00 am (PDT)

    February 16, 2023 – "IPO Black History Month Event: Successes and Challenges Faced by Leaders in the Black IP Community" (Intellectual Property Owners Association Black IP Professionals Resource Group) – 2:00 pm to 3:00 pm (ET)

    March 21-22, 2023 – National Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities and Gene Therapies (American Conference Institute) – Boston, MA

  • Strafford #1Strafford will be offering a webinar entitled "Orange Book Listing Recent Developments — Impact on Prosecution of Pharmaceutical U.S. Patent Applications, Subsequent Orange Book Listings, Hatch Waxman Litigation" on February 14, 2023 from 1:00 to 2:30 pm (EST).  Adriana L. Burgy, Mark J. Feldstein, Thomas L. Irving, and Jill K. MacAlpine of Finnegan Henderson Farabow Garrett & Dunner, and Sarah Hooson of Merck Sharp & Dohme will guide patent counsel on recent Orange Book developments; discuss Orange Book listing practices and the implications for patent prosecution, listing, and litigation; and examine contemporary thought about Form 3542 and pitfalls to avoid.  The webinar will review the following issues:

    • What are the changes and anticipated changes to the Orange Book?
    • What strategies should counsel employ when listing pharmaceutical patents in the Orange Book?

    The registration fee for the webcast is $347.  Those interested in registering for the webinar, can do so here.

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "The Myth of the Meritocracy Part 2 — Countering Myths and Overcoming Bias" on February 14, 2023 from 2:00 pm to 3:00 pm (ET).  Alex Lodge of Cargill, Inc.; Denise Robinson of The Still Center LLC; and Sanjiv Sarwate of Dell Technologies will explore how misguided confidence in meritocracy affects critical decisions and alternative paradigms that can ameliorate those effects.

    There is no registration fee for the webinar.  However, those interested in attending the webinar should register here.

  • PIUGPatent Information Users Group, Inc. (PIUG) will be offering a webinar on "Best Practices for Searching Non-Patent Literature" from 10:00 am to 11:00 am (EST) on February 15, 2023.  Christine Geluk at Librarian At Your Service LLC will explore database choices patent information professionals have for their patentability search (aka prior art) checklist, with an emphasis on publicly available databases.  The webinar will provide general search strategies for each database, and on several NPL types.

    The registration fee for the webinar is $129 for non-members or $79 for PIUG members.  Those interested in attending the webinar can register here.

  • Lex MachinaLex Machina will be offering a live webinar on the release of its 2023 Patent Litigation Report on February 15, 2023 at 9:00 am (PDT).  Aria Nejad of Lex Machina will moderate a panel consisting of Robin Davis of Woodsford, Michael Connelly of WIT Legal, and Elaine Chow of Lex Machina that will discuss patent litigation trends over the last three years; offer insights on judges, venues, parties, law firms, case filings, timing, case resolutions, findings, and damages; and look at emerging trends in connection with PTAB litigation and federal appellate patent litigation.

    Those wishing to register for the webinar can do so here.

  • IPO #2The Intellectual Property Owners Association (IPO) Black IP Professionals Resource Group will be hosting a virtual discussion entitled "IPO Black History Month Event: Successes and Challenges Faced by Leaders in the Black IP Community" on February 16, 2023 from 2:00 pm to 3:00 pm (ET).  Gaby L. Longsworth of Sterne, Kessler, Goldstein & Fox PLLC and Tony Sabeta of Aird & McBurney LP will moderate a panel consisting of Govinda Davis of Dinsmore & Shohl LLP, Eldora L. Ellison of Sterne, Kessler, Goldstein & Fox PLLC, Dara M. Kendall of Procter & Gamble Company, and Theodore (Ted) A. Wood of Wood IP will provide insights, perspectives, and strategies for thriving in the IP profession.

    There is no registration fee for the webinar.  However, those interested in attending the webinar should register here.

  • ACIAmerican Conference Institute (ACI) will be presenting a National Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities and Gene Therapies from March 21-22, 2023, in Boston, MA.  The Forum will highlight leveraging technology, safeguarding IP, and securing funding to accelerate development in mRNA, CRISPR, and CAR-T.

    The Forum promises to be a holistic, end-to-end summit for therapeutic pioneers, innovators, investors, executives and their counsel to meet, assess, and shape the future development and commercialization of these novel modalities and therapies.  Confirmed speakers include Julia Tierney (Chief of Staff, Food and Drug Administration), Anne Gussow (Supervisory Patent Examiner, Quality Assurance Specialist, USPTO), Karlheinz Skowronek (Supervisory Patent Examiner, Bioinformatics, USPTO), and Julie Wu (Supervisory Patent Examiner, Immunotherapy and Recombinant Antibodies, USPTO).

    A brochure, agenda, and registration information including lodgings can be found here.  ACI can be contacted by e-mail at customerservice@americanconference.com and by telephone at 1-888-224-2480.

    Patent Docs readers can save 10% by using promo code: D10-999-PATENTDOCS.